
“Imagine the patient.” #OmniT2I encodes feature relationships in images for CNNs, combining multi-omics + H&E to predict OS in #TCGA (C-index 0.78). Led by @PengLi_AI @ZuhairMajeed et al. @OSUCCC_James @OhioStatePIIO biorxiv.org/content/10.64898…

Physician-Scientist @OSUCCC_James in #GU #brainmet #CodetoClinic #AIinMedicine #spatialsinglecell | alumni @MDAndersonNews | #cancerfreeworld

“Imagine the patient.” #OmniT2I encodes feature relationships in images for CNNs, combining multi-omics + H&E to predict OS in #TCGA (C-index 0.78). Led by @PengLi_AI @ZuhairMajeed et al. @OSUCCC_James @OhioStatePIIO biorxiv.org/content/10.64898…

🌰Applications are OPEN for our @UroOnc Fellowship! What makes training at Ohio State special? From our complex surgical care to innovative research/mentorship, we’re taking you inside our Championship Culture🏆 Follow along as we spotlight what sets us apart! 🅾️🙌 #UroOnc

Spatial biology from routine FFPE blocks, the tissue every community practice already has. GeoMx profiling of myeloid, CD8 and endothelial compartments in sunitinib-treated ccRCC fed ML models that predicted PFS and OS in an independent cohort 🔬 Congrats @HasanovLab and team 👏 #KidneyCancer #GUonc
New from our lab @sigtrans_sttt @NaturePortfolio impact factor 81.2! #CodetoClinic Spatial features from FFPE inform ML models predicting PFS/OS in an independent RCC cohort. Thanks to @OSUCCC_James @MostafaIHA @ShriyaDeshmukh3 @EJonasch @UTMDAnderson nature.com/articles/s41392-0…

New from our lab @sigtrans_sttt @NaturePortfolio impact factor 81.2! #CodetoClinic Spatial features from FFPE inform ML models predicting PFS/OS in an independent RCC cohort. Thanks to @OSUCCC_James @MostafaIHA @ShriyaDeshmukh3 @EJonasch @UTMDAnderson nature.com/articles/s41392-0…

Proud to represent @OSUCCC_James @OSUWexMed @OSU_Urology with @HasanovLab and @lingbin_meng in Bermuda at the 9th Annual Summit on GU Malignancies!

Coming up Next: SETTING THE STAGE - RENAL CELL CARCINOMA Moderator: Dr. Scott Tykodi The session will explore translational research, HIF2α inhibitors, VHL care & AI modelling, featuring Drs. Brugarolas, Jonasch, Ball & Hasanov #DAVAGU


Some evenings remind you why you love this field. Last night in Pittsburgh was one of them. 💙 Thank you to everyone who filled the room at Cancer Updates From Major Oncology Meetings – Pittsburgh. It was an honor to co-chair this program with Dr. Adam brufsky and to share the latest in hematologic malignancies. The science was excellent, but I'll remember the energy in the room most. Oncologists, APPs, nurses, pharmacists, and fellows came together after a full day at work. The questions were thoughtful, the hallway conversations ran long, and colleagues who hadn't seen each other met up. Coming back to Pittsburgh always feels like coming home. So many of the people in that room worked with me, referred patients to me, or cared for patients alongside me over the years. The oncology community here is one of the strongest anywhere. Meetings like this matter. A trial result becomes better care only when colleagues talk it through together, compare notes, and take it back to their patients. Thank you to Total Health, our faculty, Dr. Elshad Hasanov, Dulabh Kaur Monga, Christopher Lemmon, and everyone who joined us! @UPMCHillmanCC @TotalHealthConf @CyrusKhann @HasanovLab #hemonc @oncodaily @AJMC_Journal @BloodCancerUtd @aamdsif #MedTwitter: #OncTwitter: #mmsm #lymsm , #leusm #MPNsm

📝New publication from Merve Hasanov in Neuro-Oncology Advances: Clinical factors associated with leptomeningeal disease in patients with melanoma brain metastasis doi.org/10.1093/noajnl/vdag2…

🌍 Two days of connection, learning and collaboration! The 2026 IKCC Global Kidney Cancer Summit brought together more than 50 patient advocates, healthcare professionals and kidney cancer experts from around the world in Prague, Czech Republic, on 10–11 October.

Congratulations to @OSUCCC_James, @OhioStateMedOnc, #PIIO physician-scientist, Dr. Elshad Hasanov (@HasanovLab) on receiving a @GatewayforCR award to fund ZUMRA study, a multicenter phase II clinical trial for patients with #KidneyCancer and #BrainMetastasis! ZUMRA study will test zanzalintinib alone or in combination with belzutifan in patients with untreated or progressive #BrainMetastases, a population often excluded from major clinical trials. The study will evaluate whether these treatments shrink brain metastases, while also assessing safety, duration of cancer control, and survival. An important step toward expanding treatment options and bringing hope to patients with challenging-to-treat kidney cancer. #KidneyCancer #ClinicalTrials #CancerResearch

👏Congrats to @HasanovLab on receiving a @GatewayforCR award for a multicenter phase 2 study of zanzalintinib & combination therapies in untreated or progressive brain metastases in renal cell carcinoma

🎊Congratulations🎊 to our own @eric_facs who was recognized as an @OSUCCC_James 2026 Service Line Physician Champion at the recent Annual James Physician Recognition Celebration! We’re proud to celebrate this well-deserved award and Dr. Singer’s dedication to our patients 👏

📢 Today, on World Cancer Research Day, the 5th IKCC Global Patient Survey on Kidney Cancer is now open! People who have been diagnosed with kidney cancer and carers are invited to share patient experiences and insights in the online survey: bit.ly/IKCC_Kidney_Cancer_Gl…

🧬 Join #PIIO for a Special Research Seminar featuring Dr. @HindRafei, Assistant Professor and Physician-Scientist at UT MD Anderson Cancer Center. 🔬 “Targeting cAMP signaling and metabolism to improve cellular immunotherapy in the tumor microenvironment” 📅 Sept. 16 | 12–1 PM 📍 BRT 115 🍕 Pizza will be provided #CancerResearch #Immunotherapy #CellTherapy

📝New publication from @HasanovLab & colleagues in @ESMO_Open: Era-specific prognostic factors and an interpretable machine-learning survival model for renal cell carcinoma brain metastases doi.org/10.1016/j.esmoop.202…